Ipratropium Bromide
Generic Name: ipratropium bromide
Brand Names:
Ipratropium Bromide
Ipratropium bromide is an anticholinergic agent available as a nasal spray solution (0.03%) delivering 21 mcg per spray, indicated for symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis.
Overview
Ipratropium bromide is an anticholinergic agent available as a nasal spray solution (0.03%) delivering 21 mcg per spray, indicated for symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis.
Uses
Indicated for symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Does not relieve nasal congestion, sneezing, or postnasal drip.
Dosage
Recommended dose: two sprays (42 mcg) per nostril two or three times daily (total dose 168-252 mcg/day). Initial pump priming requires seven sprays; repriming after 24 hours needs two sprays, or seven sprays if unused for more than seven days.
Side Effects
Most common: headache (9.8%), upper respiratory infection (9.8%), epistaxis (9.0%), nasal dryness (5.1%), pharyngitis (8.1%). Most adverse events were mild/moderate and self-resolving. Post-marketing: allergic reactions including rash, angioedema, urticaria, and anaphylaxis.
Interactions
No controlled clinical trials conducted. Potential for additive interaction with other concomitantly administered anticholinergic medications, including ipratropium bromide for oral inhalation.
Warnings
Immediate hypersensitivity reactions may occur including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Therapy should be discontinued if such reactions occur. Contraindicated in patients with history of hypersensitivity to atropine or its derivatives. Do not spray in eyes.
Pregnancy
Pregnancy Category B. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects. Should be used only if clearly needed. Use with caution in nursing mothers.
Storage
Store tightly closed at 20-25 degrees C (68-77 degrees F). Avoid freezing. Keep out of reach of children.
Frequently Asked Questions
What is Ipratropium Bromide used for?▼
Indicated for symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Does not relieve nasal congestion, sneezing, or postnasal drip.
What are the side effects of Ipratropium Bromide?▼
Most common: headache (9.8%), upper respiratory infection (9.8%), epistaxis (9.0%), nasal dryness (5.1%), pharyngitis (8.1%). Most adverse events were mild/moderate and self-resolving. Post-marketing: allergic reactions including rash, angioedema, urticaria, and anaphylaxis.
Can I take Ipratropium Bromide during pregnancy?▼
Pregnancy Category B. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects. Should be used only if clearly needed. Use with caution in nursing mothers.
What are the important warnings for Ipratropium Bromide?▼
Immediate hypersensitivity reactions may occur including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Therapy should be discontinued if such reactions occur. Contraindicated in patients with history of hypersensitivity to atropine or its derivatives. Do not spray in eyes.
Related Medications
Indium Metallicum
indium metallicum
Guaifenesin Directly Compressible Granules 95%
guaifenesin directly compressible granules 95%
Dosage form: POWDER. Active ingredients: GUAIFENESIN (95 mg/100mg). Category: DRUG FOR FURTHER PROCESSING.
Acer Rubrum, Acer Saccharinum And Acer Saccharum
acer rubrum, acer saccharinum and acer saccharum
Dosage form: SOLUTION. Route: INTRADERMAL, PERCUTANEOUS, SUBCUTANEOUS. Active ingredients: ACER RUBRUM POLLEN (.0003333 g/mL); ACER SACCHARINUM POLLEN (.0003333 g/mL); ACER SACCHARUM POLLEN (.0003333 g/mL). Category: BLA.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.